Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US™ View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2010-01-26

AUTHORS

A. N. A. Tosteson, T. P. Do, S. W. Wade, M. S. Anthony, R. W. Downs

ABSTRACT

During the first year of Prospective Observational Scientific Study Investigating Bone Loss Experience (POSSIBE US™), many women transitioned (i.e., discontinued or switched) from their baseline osteoporosis medication. Participants not on stable therapy at entry, with side effects, and with poor physical status were at higher risk of transitioning. Understanding factors associated with persistence may lead to improved outcomes.IntroductionPostmenopausal osteoporosis (PMO) medication use patterns may differ by treatment history and drug class. We describe these patterns among patients in primary care settings using patient-reported data.MethodsData from 3,006 participants of the POSSIBLE US™ were used to estimate the probability of a baseline PMO medication transition (i.e., discontinuation or switch) and hazard ratios (HRs) for predictors of these transitions.ResultsOne year after study entry, the probability of persisting with a baseline medication was 66% (95% CI: 64–68%). After adjusting for age and osteoporosis diagnosis, factors at entry independently associated with a higher risk of baseline medication transition were treatment status cohort, side effect severity, and OPAQ-SV physical function score. Compared to participants stable on therapy at entry, others had a higher risk, ranging from HR = 1.59 (95% CI: 1.36–1.85) for those new to therapy to HR = 2.00 (95% CI: 1.27–3.15) for those who recently augmented therapy at entry. Participants reporting moderate (HR = 1.31, 95% CI: 1.09–1.57) or severe (HR = 1.88, 95% CI: 1.49–2.39) side effects had a higher risk than those not reporting side effects. Participants reporting Osteoporosis Assessment Questionnaire-Short Version physical function scores in the lowest tertile had a higher risk (HR = 1.27, 95% CI: 1.07–1.52) than those reporting scores in the highest tertile.ConclusionBaseline osteoporosis medication transitions were common in the first year of POSSIBLE US™. Participants not on stable therapy at entry, or who reported severe side effects, or had poor physical health status were at higher risk for these transitions. More... »

PAGES

1769-1780

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00198-009-1133-5

DOI

http://dx.doi.org/10.1007/s00198-009-1133-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1042711530

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20101492


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Density Conservation Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Substitution", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Utilization", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Educational Status", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Epidemiologic Methods", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Osteoporosis, Postmenopausal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "HB 7505 Clinical Research, The Dartmouth Institute for Health Policy and Clinical Practice, Dartmouth Medical School, 1 Medical Center Drive, 03756, Lebanon, NH, USA", 
          "id": "http://www.grid.ac/institutes/grid.414049.c", 
          "name": [
            "HB 7505 Clinical Research, Dartmouth Medical School, 1 Medical Center Drive, 03756, Lebanon, NH, USA", 
            "HB 7505 Clinical Research, The Dartmouth Institute for Health Policy and Clinical Practice, Dartmouth Medical School, 1 Medical Center Drive, 03756, Lebanon, NH, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tosteson", 
        "givenName": "A. N. A.", 
        "id": "sg:person.012234200657.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012234200657.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen Inc, 1201 Amgen Court West, MS: WAWM 1111, 98119, Seattle, WA, USA", 
          "id": "http://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Amgen Inc, 1201 Amgen Court West, MS: WAWM 1111, 98119, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Do", 
        "givenName": "T. P.", 
        "id": "sg:person.0733051777.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733051777.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wade Outcomes Research and Consulting, 136 U Street, 84103, Salt Lake City, UT, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Wade Outcomes Research and Consulting, 136 U Street, 84103, Salt Lake City, UT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wade", 
        "givenName": "S. W.", 
        "id": "sg:person.0617012057.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617012057.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen Inc, One Amgen Center Drive, MS: 24-2-A, 91320, Thousand Oaks, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Amgen Inc, One Amgen Center Drive, MS: 24-2-A, 91320, Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Anthony", 
        "givenName": "M. S.", 
        "id": "sg:person.01165514160.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165514160.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Virginia Commonwealth University School of Medicine, 1101 E Marshall Street, 7-015, P.O. Box\u00a0980111, 23298-0111, Richmond, VA, USA", 
          "id": "http://www.grid.ac/institutes/grid.224260.0", 
          "name": [
            "Virginia Commonwealth University School of Medicine, 1101 E Marshall Street, 7-015, P.O. Box\u00a0980111, 23298-0111, Richmond, VA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Downs", 
        "givenName": "R. W.", 
        "id": "sg:person.0624451277.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624451277.33"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00198-008-0618-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051031077", 
          "https://doi.org/10.1007/s00198-008-0618-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-006-0073-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020337646", 
          "https://doi.org/10.1007/s00198-006-0073-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-006-0322-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012288373", 
          "https://doi.org/10.1007/s00198-006-0322-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-008-0674-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041206509", 
          "https://doi.org/10.1007/s00198-008-0674-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1477-7525-2-12", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039428500", 
          "https://doi.org/10.1186/1477-7525-2-12"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2010-01-26", 
    "datePublishedReg": "2010-01-26", 
    "description": "During the first year of Prospective Observational Scientific Study Investigating Bone Loss Experience (POSSIBE US\u2122), many women transitioned (i.e., discontinued or switched) from their baseline osteoporosis medication. Participants not on stable therapy at entry, with side effects, and with poor physical status were at higher risk of transitioning. Understanding factors associated with persistence may lead to improved outcomes.IntroductionPostmenopausal osteoporosis (PMO) medication use patterns may differ by treatment history and drug class. We describe these patterns among patients in primary care settings using patient-reported data.MethodsData from 3,006 participants of the POSSIBLE US\u2122 were used to estimate the probability of a baseline PMO medication transition (i.e., discontinuation or switch) and hazard ratios (HRs) for predictors of these transitions.ResultsOne year after study entry, the probability of persisting with a baseline medication was 66% (95% CI: 64\u201368%). After adjusting for age and osteoporosis diagnosis, factors at entry independently associated with a higher risk of baseline medication transition were treatment status cohort, side effect severity, and OPAQ-SV physical function score. Compared to participants stable on therapy at entry, others had a higher risk, ranging from HR\u2009=\u20091.59 (95% CI: 1.36\u20131.85) for those new to therapy to HR\u2009=\u20092.00 (95% CI: 1.27\u20133.15) for those who recently augmented therapy at entry. Participants reporting moderate (HR\u2009=\u20091.31, 95% CI: 1.09\u20131.57) or severe (HR\u2009=\u20091.88, 95% CI: 1.49\u20132.39) side effects had a higher risk than those not reporting side effects. Participants reporting Osteoporosis Assessment Questionnaire-Short Version physical function scores in the lowest tertile had a higher risk (HR\u2009=\u20091.27, 95% CI: 1.07\u20131.52) than those reporting scores in the highest tertile.ConclusionBaseline osteoporosis medication transitions were common in the first year of POSSIBLE US\u2122. Participants not on stable therapy at entry, or who reported severe side effects, or had poor physical health status were at higher risk for these transitions.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00198-009-1133-5", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100834", 
        "issn": [
          "0937-941X", 
          "1433-2965"
        ], 
        "name": "Osteoporosis International", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "21"
      }
    ], 
    "keywords": [
      "physical function scores", 
      "hazard ratio", 
      "high risk", 
      "medication transition", 
      "side effects", 
      "stable therapy", 
      "function scores", 
      "Prospective Observational Scientific Study", 
      "poor physical health status", 
      "Bone Loss Experience", 
      "side effect severity", 
      "medication use patterns", 
      "poor physical status", 
      "primary care setting", 
      "patient-reported data", 
      "physical health status", 
      "severe side effects", 
      "first year", 
      "baseline medication", 
      "osteoporosis medications", 
      "study entry", 
      "lowest tertile", 
      "highest tertile", 
      "medication history", 
      "ResultsOne year", 
      "improved outcomes", 
      "drug classes", 
      "care settings", 
      "treatment history", 
      "osteoporosis diagnosis", 
      "physical status", 
      "health status", 
      "effect severity", 
      "therapy", 
      "tertile", 
      "medications", 
      "risk", 
      "scores", 
      "women", 
      "participants", 
      "years", 
      "loss experience", 
      "status", 
      "Understanding factors", 
      "patients", 
      "MethodsData", 
      "cohort", 
      "diagnosis", 
      "severity", 
      "entry", 
      "outcomes", 
      "age", 
      "effect", 
      "factors", 
      "history", 
      "predictors", 
      "persistence", 
      "use patterns", 
      "patterns", 
      "setting", 
      "scientific studies", 
      "study", 
      "possible uses", 
      "uses", 
      "experience", 
      "data", 
      "ratio", 
      "probability", 
      "results", 
      "class", 
      "transition", 
      "Observational Scientific Study", 
      "baseline osteoporosis medication", 
      "IntroductionPostmenopausal osteoporosis (PMO) medication use patterns", 
      "osteoporosis (PMO) medication use patterns", 
      "baseline PMO medication transition", 
      "PMO medication transition", 
      "baseline medication transition", 
      "treatment status cohort", 
      "status cohort", 
      "OPAQ-SV physical function score", 
      "Osteoporosis Assessment Questionnaire-Short Version physical function scores", 
      "Assessment Questionnaire-Short Version physical function scores", 
      "Questionnaire-Short Version physical function scores", 
      "Version physical function scores", 
      "ConclusionBaseline osteoporosis medication transitions", 
      "osteoporosis medication transitions", 
      "varied osteoporosis medication histories", 
      "osteoporosis medication histories"
    ], 
    "name": "Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US\u2122", 
    "pagination": "1769-1780", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1042711530"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00198-009-1133-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20101492"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00198-009-1133-5", 
      "https://app.dimensions.ai/details/publication/pub.1042711530"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_522.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00198-009-1133-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00198-009-1133-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00198-009-1133-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00198-009-1133-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00198-009-1133-5'


 

This table displays all metadata directly associated to this object as RDF triples.

259 TRIPLES      22 PREDICATES      132 URIs      118 LITERALS      18 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00198-009-1133-5 schema:about N143f77a47ee649b1831c2a1d7432b571
2 N25951d8a72704128860e79c7133f0cc7
3 N30c95fcfafce42b480c169d349df101a
4 N51bb0c2fec8444528f7f858e0ccf7f0d
5 N680ddbb3ea8f417d941a941136cfcbed
6 N9139d9a0db604b4b94bc3f2aaa3df028
7 Nc4d55953b7a74e33b1e5949f47e26035
8 Nd1ec057b28184666bfaab66577240bb4
9 Ndf69f126b7c14c9cb1a99672a08c4bae
10 Nf425d8e6e7494ea6ab98520794c3737c
11 Nf531535f36654af98ebb647c869fc67a
12 anzsrc-for:11
13 anzsrc-for:1103
14 anzsrc-for:1117
15 schema:author N4b94014042c64c4e8d12f9eb1ab252c5
16 schema:citation sg:pub.10.1007/s00198-006-0073-6
17 sg:pub.10.1007/s00198-006-0322-8
18 sg:pub.10.1007/s00198-008-0618-y
19 sg:pub.10.1007/s00198-008-0674-3
20 sg:pub.10.1186/1477-7525-2-12
21 schema:datePublished 2010-01-26
22 schema:datePublishedReg 2010-01-26
23 schema:description During the first year of Prospective Observational Scientific Study Investigating Bone Loss Experience (POSSIBE US™), many women transitioned (i.e., discontinued or switched) from their baseline osteoporosis medication. Participants not on stable therapy at entry, with side effects, and with poor physical status were at higher risk of transitioning. Understanding factors associated with persistence may lead to improved outcomes.IntroductionPostmenopausal osteoporosis (PMO) medication use patterns may differ by treatment history and drug class. We describe these patterns among patients in primary care settings using patient-reported data.MethodsData from 3,006 participants of the POSSIBLE US™ were used to estimate the probability of a baseline PMO medication transition (i.e., discontinuation or switch) and hazard ratios (HRs) for predictors of these transitions.ResultsOne year after study entry, the probability of persisting with a baseline medication was 66% (95% CI: 64–68%). After adjusting for age and osteoporosis diagnosis, factors at entry independently associated with a higher risk of baseline medication transition were treatment status cohort, side effect severity, and OPAQ-SV physical function score. Compared to participants stable on therapy at entry, others had a higher risk, ranging from HR = 1.59 (95% CI: 1.36–1.85) for those new to therapy to HR = 2.00 (95% CI: 1.27–3.15) for those who recently augmented therapy at entry. Participants reporting moderate (HR = 1.31, 95% CI: 1.09–1.57) or severe (HR = 1.88, 95% CI: 1.49–2.39) side effects had a higher risk than those not reporting side effects. Participants reporting Osteoporosis Assessment Questionnaire-Short Version physical function scores in the lowest tertile had a higher risk (HR = 1.27, 95% CI: 1.07–1.52) than those reporting scores in the highest tertile.ConclusionBaseline osteoporosis medication transitions were common in the first year of POSSIBLE US™. Participants not on stable therapy at entry, or who reported severe side effects, or had poor physical health status were at higher risk for these transitions.
24 schema:genre article
25 schema:inLanguage en
26 schema:isAccessibleForFree false
27 schema:isPartOf N41f8feef316d4442b6a9db82a64e52e1
28 Ncc6b4803683847de82834c01a28a93b0
29 sg:journal.1100834
30 schema:keywords Assessment Questionnaire-Short Version physical function scores
31 Bone Loss Experience
32 ConclusionBaseline osteoporosis medication transitions
33 IntroductionPostmenopausal osteoporosis (PMO) medication use patterns
34 MethodsData
35 OPAQ-SV physical function score
36 Observational Scientific Study
37 Osteoporosis Assessment Questionnaire-Short Version physical function scores
38 PMO medication transition
39 Prospective Observational Scientific Study
40 Questionnaire-Short Version physical function scores
41 ResultsOne year
42 Understanding factors
43 Version physical function scores
44 age
45 baseline PMO medication transition
46 baseline medication
47 baseline medication transition
48 baseline osteoporosis medication
49 care settings
50 class
51 cohort
52 data
53 diagnosis
54 drug classes
55 effect
56 effect severity
57 entry
58 experience
59 factors
60 first year
61 function scores
62 hazard ratio
63 health status
64 high risk
65 highest tertile
66 history
67 improved outcomes
68 loss experience
69 lowest tertile
70 medication history
71 medication transition
72 medication use patterns
73 medications
74 osteoporosis (PMO) medication use patterns
75 osteoporosis diagnosis
76 osteoporosis medication histories
77 osteoporosis medication transitions
78 osteoporosis medications
79 outcomes
80 participants
81 patient-reported data
82 patients
83 patterns
84 persistence
85 physical function scores
86 physical health status
87 physical status
88 poor physical health status
89 poor physical status
90 possible uses
91 predictors
92 primary care setting
93 probability
94 ratio
95 results
96 risk
97 scientific studies
98 scores
99 setting
100 severe side effects
101 severity
102 side effect severity
103 side effects
104 stable therapy
105 status
106 status cohort
107 study
108 study entry
109 tertile
110 therapy
111 transition
112 treatment history
113 treatment status cohort
114 use patterns
115 uses
116 varied osteoporosis medication histories
117 women
118 years
119 schema:name Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US™
120 schema:pagination 1769-1780
121 schema:productId N77f02d397e654e7588845c0a41458315
122 N82ad2f0e52214574a520e71cf5232173
123 Nbc59d04d587b4c9f955f5142b5136519
124 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042711530
125 https://doi.org/10.1007/s00198-009-1133-5
126 schema:sdDatePublished 2021-12-01T19:24
127 schema:sdLicense https://scigraph.springernature.com/explorer/license/
128 schema:sdPublisher Nca10b8fdbbc7404db11e503644eab85e
129 schema:url https://doi.org/10.1007/s00198-009-1133-5
130 sgo:license sg:explorer/license/
131 sgo:sdDataset articles
132 rdf:type schema:ScholarlyArticle
133 N143f77a47ee649b1831c2a1d7432b571 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Epidemiologic Methods
135 rdf:type schema:DefinedTerm
136 N25951d8a72704128860e79c7133f0cc7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Educational Status
138 rdf:type schema:DefinedTerm
139 N25fece009ac94837aa657112a724a960 rdf:first sg:person.01165514160.38
140 rdf:rest N35ee068d5f054215a36d22207030d789
141 N30c95fcfafce42b480c169d349df101a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Middle Aged
143 rdf:type schema:DefinedTerm
144 N35ee068d5f054215a36d22207030d789 rdf:first sg:person.0624451277.33
145 rdf:rest rdf:nil
146 N41f8feef316d4442b6a9db82a64e52e1 schema:volumeNumber 21
147 rdf:type schema:PublicationVolume
148 N4b94014042c64c4e8d12f9eb1ab252c5 rdf:first sg:person.012234200657.45
149 rdf:rest N4d5fe2d10fb240e39df6d5c7f83f163c
150 N4d5fe2d10fb240e39df6d5c7f83f163c rdf:first sg:person.0733051777.39
151 rdf:rest N529e8f46392940128525ba75ff827dfa
152 N51bb0c2fec8444528f7f858e0ccf7f0d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Drug Utilization
154 rdf:type schema:DefinedTerm
155 N529e8f46392940128525ba75ff827dfa rdf:first sg:person.0617012057.00
156 rdf:rest N25fece009ac94837aa657112a724a960
157 N680ddbb3ea8f417d941a941136cfcbed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Drug Substitution
159 rdf:type schema:DefinedTerm
160 N77f02d397e654e7588845c0a41458315 schema:name pubmed_id
161 schema:value 20101492
162 rdf:type schema:PropertyValue
163 N82ad2f0e52214574a520e71cf5232173 schema:name dimensions_id
164 schema:value pub.1042711530
165 rdf:type schema:PropertyValue
166 N9139d9a0db604b4b94bc3f2aaa3df028 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Aged
168 rdf:type schema:DefinedTerm
169 Nbc59d04d587b4c9f955f5142b5136519 schema:name doi
170 schema:value 10.1007/s00198-009-1133-5
171 rdf:type schema:PropertyValue
172 Nc4d55953b7a74e33b1e5949f47e26035 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Humans
174 rdf:type schema:DefinedTerm
175 Nca10b8fdbbc7404db11e503644eab85e schema:name Springer Nature - SN SciGraph project
176 rdf:type schema:Organization
177 Ncc6b4803683847de82834c01a28a93b0 schema:issueNumber 10
178 rdf:type schema:PublicationIssue
179 Nd1ec057b28184666bfaab66577240bb4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Female
181 rdf:type schema:DefinedTerm
182 Ndf69f126b7c14c9cb1a99672a08c4bae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Treatment Outcome
184 rdf:type schema:DefinedTerm
185 Nf425d8e6e7494ea6ab98520794c3737c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Osteoporosis, Postmenopausal
187 rdf:type schema:DefinedTerm
188 Nf531535f36654af98ebb647c869fc67a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Bone Density Conservation Agents
190 rdf:type schema:DefinedTerm
191 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
192 schema:name Medical and Health Sciences
193 rdf:type schema:DefinedTerm
194 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
195 schema:name Clinical Sciences
196 rdf:type schema:DefinedTerm
197 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
198 schema:name Public Health and Health Services
199 rdf:type schema:DefinedTerm
200 sg:journal.1100834 schema:issn 0937-941X
201 1433-2965
202 schema:name Osteoporosis International
203 schema:publisher Springer Nature
204 rdf:type schema:Periodical
205 sg:person.01165514160.38 schema:affiliation grid-institutes:grid.417886.4
206 schema:familyName Anthony
207 schema:givenName M. S.
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165514160.38
209 rdf:type schema:Person
210 sg:person.012234200657.45 schema:affiliation grid-institutes:grid.414049.c
211 schema:familyName Tosteson
212 schema:givenName A. N. A.
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012234200657.45
214 rdf:type schema:Person
215 sg:person.0617012057.00 schema:affiliation grid-institutes:None
216 schema:familyName Wade
217 schema:givenName S. W.
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617012057.00
219 rdf:type schema:Person
220 sg:person.0624451277.33 schema:affiliation grid-institutes:grid.224260.0
221 schema:familyName Downs
222 schema:givenName R. W.
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624451277.33
224 rdf:type schema:Person
225 sg:person.0733051777.39 schema:affiliation grid-institutes:grid.417886.4
226 schema:familyName Do
227 schema:givenName T. P.
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733051777.39
229 rdf:type schema:Person
230 sg:pub.10.1007/s00198-006-0073-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020337646
231 https://doi.org/10.1007/s00198-006-0073-6
232 rdf:type schema:CreativeWork
233 sg:pub.10.1007/s00198-006-0322-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012288373
234 https://doi.org/10.1007/s00198-006-0322-8
235 rdf:type schema:CreativeWork
236 sg:pub.10.1007/s00198-008-0618-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1051031077
237 https://doi.org/10.1007/s00198-008-0618-y
238 rdf:type schema:CreativeWork
239 sg:pub.10.1007/s00198-008-0674-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041206509
240 https://doi.org/10.1007/s00198-008-0674-3
241 rdf:type schema:CreativeWork
242 sg:pub.10.1186/1477-7525-2-12 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039428500
243 https://doi.org/10.1186/1477-7525-2-12
244 rdf:type schema:CreativeWork
245 grid-institutes:None schema:alternateName Wade Outcomes Research and Consulting, 136 U Street, 84103, Salt Lake City, UT, USA
246 schema:name Wade Outcomes Research and Consulting, 136 U Street, 84103, Salt Lake City, UT, USA
247 rdf:type schema:Organization
248 grid-institutes:grid.224260.0 schema:alternateName Virginia Commonwealth University School of Medicine, 1101 E Marshall Street, 7-015, P.O. Box 980111, 23298-0111, Richmond, VA, USA
249 schema:name Virginia Commonwealth University School of Medicine, 1101 E Marshall Street, 7-015, P.O. Box 980111, 23298-0111, Richmond, VA, USA
250 rdf:type schema:Organization
251 grid-institutes:grid.414049.c schema:alternateName HB 7505 Clinical Research, The Dartmouth Institute for Health Policy and Clinical Practice, Dartmouth Medical School, 1 Medical Center Drive, 03756, Lebanon, NH, USA
252 schema:name HB 7505 Clinical Research, Dartmouth Medical School, 1 Medical Center Drive, 03756, Lebanon, NH, USA
253 HB 7505 Clinical Research, The Dartmouth Institute for Health Policy and Clinical Practice, Dartmouth Medical School, 1 Medical Center Drive, 03756, Lebanon, NH, USA
254 rdf:type schema:Organization
255 grid-institutes:grid.417886.4 schema:alternateName Amgen Inc, 1201 Amgen Court West, MS: WAWM 1111, 98119, Seattle, WA, USA
256 Amgen Inc, One Amgen Center Drive, MS: 24-2-A, 91320, Thousand Oaks, CA, USA
257 schema:name Amgen Inc, 1201 Amgen Court West, MS: WAWM 1111, 98119, Seattle, WA, USA
258 Amgen Inc, One Amgen Center Drive, MS: 24-2-A, 91320, Thousand Oaks, CA, USA
259 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...